Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; water for injections - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use only in persons aged 5 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; water for injections - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use only in persons aged 5 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 29.12 mg (equivalent: tapentadol, qty 25 mg) - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; purified talc; macrogol 6000; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 232.96 mg (equivalent: tapentadol, qty 200 mg) - tablet, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; colloidal anhydrous silica; iron oxide red; lactose monohydrate; titanium dioxide; purified talc; microcrystalline cellulose; macrogol 6000; propylene glycol - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 174.72 mg (equivalent: tapentadol, qty 150 mg) - tablet, modified release - excipient ingredients: propylene glycol; magnesium stearate; iron oxide red; hypromellose; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; macrogol 6000; purified talc; iron oxide yellow - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.